Medical/Pharmaceuticals

Neomorph Announces Multi-Target Collaboration with Novo Nordisk to Discover Novel Molecular Glue Degraders for Cardiometabolic and Rare Diseases

* Collaboration leverages Neomorph's leading molecular glue discovery platform and Novo Nordisk's extensive expertise in cardiometabolic and rare diseases * Total potential deal value of $1.46B across multiple targets SAN DIEGO, Feb. 27, 2024 /PRNewswire/ -- Neomorph, Inc. today announced it ...

2024-02-27 01:06 1694

OVER HALF OF AUSTRALIAN WOMEN FEEL THEIR PAIN IS IGNORED OR DISMISSED - HIGHLIGHTING NATIONAL GENDER PAIN GAP

* New research from Nurofen reveals a national Gender Pain Gap in Australia – with 55% of women feeling they have had their pain ignored or dismissed compared to just 48% of men1 * Significantly more women than men think the reason they haven't received a diagnosis for their pain or is taki...

2024-02-26 21:01 1358

Waters Announces Seamless HPLC/UPLC Data Bridge for Light Scattering, Integrating Essential Instruments for Large Molecule Characterization

News Summary: * Waters now enables seamless connectivity between its liquid chromatography (LC) systems and multi-angle light-scattering instruments (MALS) for improved ease-of-use, efficiency, and data confidence in characterizing large molecules. * HPLC CONNECT™ software accelerates precise...

2024-02-26 21:00 1407

Encouraging Initial Data from CYP-006TK Diabetic Foot Ulcer Clinical Trial

MELBOURNE, Australia, Feb. 26, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, has completed initial analysis of wound surface area in the first 16 patients in its Phase 1 clinical...

2024-02-26 14:37 1542

Operation Smile and Beast Philanthropy Spotlight Global Need for Access to Surgical Care

VIRGINIA BEACH, Va., Feb. 25, 2024 /PRNewswire/ -- Global nonprofit Operation Smile today announced its partnership with Beast Philanthropy, the philanthropic arm of Mr. Beast that leverages the power of social media platforms to raise funds and leave a lasting impact. Operation Smile bridges th...

2024-02-26 10:10 1251

Siriraj Hospital Expands Services to Provide Advanced Medical Care, Highlights State-of-the-Art Technology for Cancer Treatment

BANGKOK, Feb. 26, 2024 /PRNewswire/ -- Cancer continues to be one of the major health crises globally and inThailand. Siriraj Hospital, recognized as one of the largest and leading hospitals inThailand, demonstrates its readiness and dedication to delivering comprehensive medical services, includ...

2024-02-26 08:00 2027

Cure Brain Cancer Foundation CEO Lance Kawaguchi Completes SouthPoleTrek4Cancer, Raises Over $1 Million for Cancer Research

SYDNEY, Feb. 26, 2024 /PRNewswire/ -- In an unprecedented feat of endurance and dedication to cancer research,Lance Kawaguchi, Chief Executive Officer of Cure Brain Cancer Foundation, successfully completed a challenging trek at the South Pole representing more than 20 charities across six countr...

2024-02-26 06:00 1328

Pierre Fabre Laboratories, committed to combating rare pediatric diseases via innovative therapies

70% of rare genetic diseases start in childhood[1,2] CASTRES, France, Feb. 23, 2024 /PRNewswire/ -- Rare Disease Day® will be held onFebruary 29, an opportunity for Pierre Fabre Laboratories to reiterate our desire to provide innovative prescription drugs to children, as young patients require a...

2024-02-23 18:23 1769

CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy

Committee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing authorization (CMA) for sparsentan for the treatment of IgA nephropathy (IgAN) inEurope Positive CHMP opinion is based on pivotal phase-III PROTECT study results European Commission decision is...

2024-02-23 15:00 1729

Kakao Brain Debuts 'KARA-CXR', a Web-Based Radiology Report Service Powered by Large-Scale AI

"AI Assistant for Radiologists" * Kakao Brain introduced last month a web-based radiology report Research Use Only (RUO) service powered by its large-scale artificial intelligence (AI), "KARA-CXR." * Kakao Brain plans to expand the interactive functions supporting various imaging medical exa...

2024-02-22 21:00 2002

Telix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage Pipeline

MELBOURNE, Australia, Feb. 22, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its results for the financial year ended31 December 2023. All figures are in AUD$ unless otherwise stated.[1] 2023 highlights * Total Group revenue of $502.5M, an...

2024-02-22 17:31 2299

Everest Medicines' Partner Pfizer Announces European Commission Approves VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis

--VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU-- SHANGHAI, Feb. 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company")'s partner Pfizer Inc. (NYSE: PFE) announced that the ...

2024-02-22 08:59 2042

Astonishing brain tumour research wins the BIAL Award in Biomedicine 2023 worth 300,000 Euro

PORTO, Portugal, Feb. 21, 2024 /PRNewswire/ -- A team of researchers from Germany, the USA, the UK, and Norway won the third edition of the BIAL Award in Biomedicine , a300,000 Euro prize promoted by the BIAL Foundation

2024-02-21 16:00 1848

Findings of a Phase III Clinical Study of Sanbexin® Sublingual Tablets Published in JAMA

NANJING, China, Feb. 21, 2024 /PRNewswire/ -- On February 19, 2024, the Journal of American Medical Association•Neurology (JAMA NEUROLOGY, IF: 29.0) published online the key findings of a phase III clinical study (NCT04950920) (the "TASTE-SL Study") investigating Sanbexin® (a combination of edara...

2024-02-21 12:26 2358

Everest Medicines' Licensing Partner Venatorx Pharmaceuticals Announces Publication of Positive Results from Cefepime-Taniborbactam's Phase 3 CERTAIN-1 Study in New England Journal of Medicine

--Cefepime-taniborbactam was superior to meropenem for the composite efficacy endpoint with composite efficacy sustained at late follow-up visit-- SHANGHAI, Feb. 21, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK)'s licensing partner, Venatorx Pharmaceuticals announced that The New England ...

2024-02-21 09:00 3296

Datasea Establishes Joint Venture Company to Further Penetrate the Estimated Approximately 527.8 billion US Dollars 5G Market in China

New Entity to be Focused on Increasing Scale of Datasea's 5G Services Utilizing Artificial Intelligence, which is Expected to Drive Significant Revenue in 2024 BEIJING, Feb. 20, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada incorporated digital technology ...

2024-02-21 01:31 1547

MediThinQ Marks Milestone as First Asian Startup to Globally Launch XR Surgical Displays, Securing Key Partnerships and Multimillion-Dollar Investment

SINGAPORE, Feb. 20, 2024 /PRNewswire/ -- MediThinQ, a pioneering Korean startup specialising in extended reality (XR) wearable displays for surgery, is making waves as the first Asian startup to globally launch XR surgical displays. The company has successfully secured significant deals with indu...

2024-02-20 14:00 2162

Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA

ROCKVILLIE, MD. and SUZHOU, China, Feb. 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major di...

2024-02-20 08:22 3945

HKUST Neuroscientists Develop Highly Accurate Universal Diagnostic Blood Test for Alzheimer's Disease and Mild Cognitive Impairment

At a glance: * Remarkably high accuracy rate – over 96% for AD and 87% for MCI; * Applicable across diverse ethnic populations, including Chinese and European; * Enables early detection of AD and subsequent progression; * Captures multiple AD-associated biological pathways; * A game-chan...

2024-02-19 20:18 2030

SIBIONICS Announced to Exhibit at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

The company will be hosting an influencer meeting during the conference LOS ANGELES, Feb. 19, 2024 /PRNewswire/ -- SIBIONICS, the world's third-largest Continuous Glucose Monitoring (CGM) System brand, announced the company will be exhibiting at the International Fair of New Technologies in Diab...

2024-02-19 10:55 2209
1 ... 52535455565758 ... 396

Week's Top Stories